These include alterations in the anaplastic lymphoma kinase (ALK), MET proto-oncogene, receptor tyrosine kinase (MET), human epidermal growth factor receptor 2 (HER2), and ROS1 proto-oncogene receptor tyrosine kinase (ROS1) and account to 9–16%of NSCLC cases. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.